Quarterly ResultAug 4, 2026, 07:46 AM
Faeth Therapeutics Q2 Net Loss $16.0M; Cash $186.4M; Name Changed to FTH
AI Summary
Faeth Therapeutics (formerly Sensei Biotherapeutics) reported a net loss of $16.0 million, or $2.84 per share, for the second quarter of 2026. The company held $186.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026. Key operational updates include dosing the first patient in the Phase 1b/2 PIK-101 trial for HR+ breast cancer and remaining on track for topline results from the Phase 2 PIK-201 trial in endometrial cancer by year-end. The company officially changed its name to Faeth Therapeutics, Inc. and began trading under the ticker "FTH" in June 2026, following a $200 million PIPE financing.
Key Highlights
- Net loss was $16.0 million ($2.84 per share) for the second quarter of 2026.
- Cash, cash equivalents, and marketable securities totaled $186.4 million as of June 30, 2026.
- Research and development expenses increased to $9.2 million in Q2 2026.
- General and administrative expenses rose to $9.2 million in Q2 2026.
- Company changed its name to Faeth Therapeutics, Inc. and ticker to "FTH" in June 2026.
- First patient dosed in Phase 1b/2 PIK-101 trial for HR+ breast cancer in April.
- Topline results from Phase 2 PIK-201 trial in endometrial cancer expected by year-end.
Price Impact
More from SNSE